[糖异生抑制剂2-(3-甲基肉桂酰腙)丙酸酯（MCHP）的临床试验结果]
[Results of clinical trials with the gluconeogenesis inhibitor 2-(3-methylcinnamylhydrazono)-propionate (MCHP)].
作者信息
Paschke R, Schwedes U, Kühnle H, Peter J, Schmeidl R, Usadel K H
机构信息
II. Medizinische Klinik, Klinkum Mannheim der Universität Heidelberg, Mannheim.
出版信息
Klin Wochenschr. 1989 Apr 17;67(8):431-7. doi: 10.1007/BF01725138.
Many compounds which directly or indirectly inhibit gluconeogenesis have been described. Some of them showed hypoglycemic action in animal experiments. 2-(3-Methylcinnamylhydrazono)-Propionat (MCHP) a derivative of hydrazine demonstrated marked hypoglycemic action in animal experiments. Nontheless the administration of MCHP to type II diabetic patients showed no hypoglycemic action. Clinical or biochemical sideeffects could not be observed.
许多直接或间接抑制糖异生的化合物已被描述。其中一些在动物实验中表现出降血糖作用。2-（3-甲基肉桂酰肼基）-丙酸酯（MCHP），一种肼的衍生物，在动物实验中表现出显著的降血糖作用。然而，对II型糖尿病患者施用MCHP并未显示出降血糖作用。未观察到临床或生化副作用。
Zotero 插件